Sarah K. Tasian

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · New England Journal of Medicine · 2014 · 1.4K citations · Full text

Life Sciences, Genetics, Oncology +17

JAK mutations in high-risk childhood acute lymphoblastic leukemia

Charles G. Mullighan, Jinghui Zhang, Richard C. Harvey et al. · Proceedings of the National Academy of Sciences · 2009 · 560 citations · Full text

Medicine, Hematology, Oncology +17

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Saar Gill, Sarah K. Tasian, Marco Ruella et al. · Blood · 2014 · 491 citations · Full text

Life Sciences, Immunology, Oncology +17

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Shannon L. Maude, Sarah K. Tasian, Tiffaney L. Vincent et al. · Blood · 2012 · 291 citations

Medicine, Oncology, Pharmacology +13

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study

I‐Ming Chen, Richard C. Harvey, Charles G. Mullighan et al. · Blood · 2012 · 247 citations · Full text

Medicine, Oncology, Pediatrics +15